Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy.
Graefes Arch Clin Exp Ophthalmol
; 247(5): 609-18, 2009 May.
Article
in En
| MEDLINE
| ID: mdl-19148667
ABSTRACT
PURPOSE:
To examine the effect of intravitreal injections of bevacizumab for myopic choroidal neovascularization (myopic CNV) that was refractory to or recurred after photodynamic therapy (PDT).METHODS:
Sixteen eyes of 16 consecutive patients with myopic CNVs that were refractory to or had recurred after PDT were studied. The patients were divided into two groups; group 1 consisted of six patients whose CNV recurred after being closed by PDT, and group 2 consisted of ten patients whose CNV did not respond to an earlier treatment. All of the eyes were injected intravitreally with 1.25 mg bevacizumab. The best-corrected visual acuity (BCVA) and fluorescein angiograms (FA) were assessed in both groups.RESULTS:
The mean follow-up period was 15.1 +/- 3.6 months. Patients received a mean of 1.8 +/- 0.8 injections. The mean BCVA in the 16 patients at the final visit was significantly improved over that before the injection. Dye leakage had disappeared in 83.3% of group 1, and in all of the eyes of group 2 at the final visit.CONCLUSIONS:
Intravitreal bevacizumab is effective for myopic CNVs that were either refractory to PDT or had recurred after being regressed by PDT.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Photochemotherapy
/
Choroidal Neovascularization
/
Angiogenesis Inhibitors
/
Myopia, Degenerative
/
Antibodies, Monoclonal
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Graefes Arch Clin Exp Ophthalmol
Year:
2009
Document type:
Article
Affiliation country:
Japón